Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Arthritis Rheumatol. 2020 May 18;72(7):1049–1058. doi: 10.1002/art.41246

Figure 2: The long-term impact of ideal disease-modifying therapy in predominately fibrotic phenotype on SSc outcomes (in comparison to HSCT).

Figure 2:

DMT Disease Modifying Therapy, HSCT Hematopetic Stem Cell Therapy, DLCO diffusion capacity for carbon monoxide, FVC forced vital capacity, MRSS Modified Rodnan Skin Score, HAQ Health Assessment Questionnaire